{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T20:38:58Z","timestamp":1773088738592,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","jada.ada.org","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of the American Dental Association"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.adaj.2019.01.028","type":"journal-article","created":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T13:00:50Z","timestamp":1558702850000},"page":"556-561","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Oral adverse reactions associated with etoricoxib, a common pain medication"],"prefix":"10.1016","volume":"150","author":[{"given":"Jeremy","family":"Edel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilena","family":"Vered","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osnat","family":"Grinstein-Koren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dalit","family":"Porat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludmila","family":"Lukach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacob","family":"Pettesh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Kelner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clariel","family":"Ianculovici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilana","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.adaj.2019.01.028_bib1","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1472-8206.2011.00991.x","article-title":"Adverse drug reactions associated with the use of NSAIDs: a case\/non-case analysis of spontaneous reports from the French pharmacovigilance database 2002-2006","volume":"27","author":"Lapeyre-Mestrea","year":"2013","journal-title":"Fundam Clin Pharmacol"},{"issue":"6A","key":"10.1016\/j.adaj.2019.01.028_bib2","doi-asserted-by":"crossref","first-page":"72S","DOI":"10.1016\/S0002-9343(99)00370-8","article-title":"General tolerability and use of nonsteroidal anti-inflammatory drugs","volume":"107","author":"Mandell","year":"1999","journal-title":"Am J Med"},{"issue":"11","key":"10.1016\/j.adaj.2019.01.028_bib3","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1517\/14656566.2.11.1859","article-title":"COX-2 inhibitors compared and contrasted","volume":"2","author":"Bennett","year":"2001","journal-title":"Expert Opin Pharmacother"},{"issue":"8","key":"10.1016\/j.adaj.2019.01.028_bib4","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s00228-008-0497-3","article-title":"Was the thrombotic risk of rofecoxib predictable from the French Pharmacovigilance Database before 30 September 2004?","volume":"64","author":"Sommet","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.adaj.2019.01.028_bib6","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S1081-1206(10)61205-7","article-title":"Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema","volume":"95","author":"S\u00e1nchez-Borges","year":"2005","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/j.adaj.2019.01.028_bib7","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S1081-1206(10)61378-6","article-title":"Safety of etoricoxib, a specific cyclooxygenase-2 inhibitor, in asthmatic patients with aspirin-exacerbated respiratory disease","volume":"97","author":"El Miedany","year":"2006","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"2","key":"10.1016\/j.adaj.2019.01.028_bib8","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S1081-1206(10)60691-6","article-title":"Tolerance to etoricoxib in 37 patients with urticaria and angioedema induced by nonsteroidal anti-inflammatory drugs","volume":"98","author":"Muratore","year":"2007","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"6","key":"10.1016\/j.adaj.2019.01.028_bib9","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1111\/j.1365-2230.2007.02464.x","article-title":"Etoricoxib challenge in patients with chronic urticaria with NSAID intolerance","volume":"32","author":"Asero","year":"2007","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"10.1016\/j.adaj.2019.01.028_bib10","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1177\/039463200902200431","article-title":"Long-term tolerability of etoricoxib in patients with previous reactions to non-steroidal anti-inflammatory drugs","volume":"22","author":"Di Leo","year":"2009","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"1","key":"10.1016\/j.adaj.2019.01.028_bib11","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/7140.2006.00012","article-title":"Adverse cutaneous reactions to selective cyclooxygenase 2 inhibitors: experience of an Italian drug-surveillance center","volume":"10","author":"Atzori","year":"2006","journal-title":"J\u00a0Cutan Med Surg"},{"issue":"3","key":"10.1016\/j.adaj.2019.01.028_bib12","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1159\/000112930","article-title":"Etoricoxib-induced erythema-multiforme-like eruption","volume":"216","author":"Thirion","year":"2008","journal-title":"Dermatology"},{"issue":"11","key":"10.1016\/j.adaj.2019.01.028_bib13","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1111\/j.1398-9995.2011.02684.x","article-title":"Response to a selective COX-2 inhibitor in patients with urticaria\/angioedema induced by nonsteroidal anti-inflammatory drugs","volume":"66","author":"Do\u00f1a","year":"2011","journal-title":"Allergy"},{"issue":"6","key":"10.1016\/j.adaj.2019.01.028_bib14","first-page":"216","article-title":"Long-term tolerability of etoricoxib in different types of NSAID-intolerant subjects","volume":"42","author":"Pagani","year":"2010","journal-title":"Eur Ann Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.adaj.2019.01.028_bib15","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1111\/ijd.12154","article-title":"Etoricoxib-induced toxic epidermal necrolysis","volume":"53","author":"Moutran","year":"2014","journal-title":"Int J Dermatol"},{"issue":"10","key":"10.1016\/j.adaj.2019.01.028_bib16","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/j.1346-8138.2010.00893.x","article-title":"Etoricoxib-induced toxic epidermal necrolysis: successful treatment with infliximab","volume":"37","author":"Kreft","year":"2010","journal-title":"J\u00a0Dermatol"},{"issue":"3","key":"10.1016\/j.adaj.2019.01.028_bib17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.4103\/ijp.IJP_39_17","article-title":"Etoricoxib-induced toxic epidermal necrolysis: a fatal case report","volume":"50","author":"Roy","year":"2018","journal-title":"Indian J Pharmacol"},{"issue":"6","key":"10.1016\/j.adaj.2019.01.028_bib18","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/jcpt.12445","article-title":"Mucosal exfoliation as a selective reaction to etoricoxib","volume":"41","author":"Patan\u00e8","year":"2016","journal-title":"J\u00a0Clin Pharm Ther"},{"key":"10.1016\/j.adaj.2019.01.028_bib19","unstructured":"ICH GCP. ICH Harmonised Guideline Integrated Addendum to ICH E6(R1): Guideline for Good Clinical Practice ICH E6(R2) ICH Consensus Guideline. Available at: https:\/\/ichgcp.net\/. Accessed April 16, 2019."},{"key":"10.1016\/j.adaj.2019.01.028_bib20","unstructured":"World Health Organization. Safety of medicines: adverse drug reactions. Available at: https:\/\/www.who.int\/medicines\/regulation\/medicines-safety\/M_SBN_Jun18.pdf. Accessed April 16, 2019."},{"issue":"7","key":"10.1016\/j.adaj.2019.01.028_bib21","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/j.1365-2222.2007.02742.x","article-title":"Delayed drug hypersensitivity reactions: new concepts","volume":"37","author":"Posadas","year":"2007","journal-title":"Clin Exp Allergy"},{"issue":"4","key":"10.1016\/j.adaj.2019.01.028_bib22","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1684\/ejd.2010.0980","article-title":"A\u00a0three-year-analysis of fixed drug eruptions in hospital settings in France","volume":"20","author":"Brahimi","year":"2010","journal-title":"Eur J Dermatol"},{"issue":"4","key":"10.1016\/j.adaj.2019.01.028_bib23","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1177\/154411130401500405","article-title":"Adverse drug reactions in the orofacial region","volume":"15","author":"Scully","year":"2004","journal-title":"Crit Rev Oral Biol Med"}],"updated-by":[{"DOI":"10.1016\/j.adaj.2019.07.002","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000}}],"container-title":["The Journal of the American Dental Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002817719300455?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002817719300455?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,12,15]],"date-time":"2020-12-15T11:10:08Z","timestamp":1608030608000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002817719300455"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["S0002817719300455"],"URL":"https:\/\/doi.org\/10.1016\/j.adaj.2019.01.028","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.adaj.2019.07.002","asserted-by":"object"}]},"ISSN":["0002-8177"],"issn-type":[{"value":"0002-8177","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral adverse reactions associated with etoricoxib, a common pain medication","name":"articletitle","label":"Article Title"},{"value":"The Journal of the American Dental Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.adaj.2019.01.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American Dental Association. All rights reserved.","name":"copyright","label":"Copyright"}]}}